Brokerages forecast that Humana Inc (NYSE:HUM) will post sales of $14.12 billion for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Humana’s earnings, with estimates ranging from $13.96 billion to $14.32 billion. Humana posted sales of $13.76 billion during the same quarter last year, which suggests a positive year over year growth rate of 2.6%. The business is scheduled to issue its next earnings report on Wednesday, May 2nd.
According to Zacks, analysts expect that Humana will report full year sales of $14.12 billion for the current year, with estimates ranging from $55.63 billion to $56.19 billion. For the next year, analysts expect that the company will post sales of $59.97 billion per share, with estimates ranging from $59.07 billion to $60.65 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Humana.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The firm had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same period in the previous year, the company posted $2.34 earnings per share. The company’s quarterly revenue was up 2.4% compared to the same quarter last year.
Several brokerages recently issued reports on HUM. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $294.00 price target on the stock in a research note on Monday, February 12th. JPMorgan Chase & Co. boosted their price target on Humana from $253.00 to $271.00 and gave the company a “neutral” rating in a research note on Monday, February 12th. Deutsche Bank boosted their price target on Humana from $259.00 to $270.00 and gave the company a “hold” rating in a research note on Friday, February 9th. Oppenheimer boosted their price target on Humana from $275.00 to $305.00 and gave the company an “outperform” rating in a research note on Thursday, February 8th. Finally, Leerink Swann boosted their price target on Humana from $280.00 to $300.00 and gave the company an “outperform” rating in a research note on Thursday, February 8th. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Humana has a consensus rating of “Buy” and an average target price of $270.47.
In other news, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the transaction, the senior vice president now directly owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Timothy S. Huval sold 1,382 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total value of $340,027.28. Following the completion of the transaction, the vice president now directly owns 11,557 shares in the company, valued at $2,843,484.28. The disclosure for this sale can be found here. Insiders sold a total of 40,579 shares of company stock worth $10,842,942 over the last three months. 0.80% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the business. Certified Advisory Corp acquired a new position in Humana during the 4th quarter worth $109,000. Fieldpoint Private Securities LLC bought a new stake in shares of Humana during the 3rd quarter valued at $115,000. American Beacon Advisors Inc. bought a new stake in shares of Humana during the 4th quarter valued at $122,000. ClariVest Asset Management LLC bought a new stake in shares of Humana in the 3rd quarter valued at $144,000. Finally, YorkBridge Wealth Partners LLC increased its position in shares of Humana by 99.0% in the 4th quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock valued at $159,000 after buying an additional 297 shares in the last quarter. 96.84% of the stock is currently owned by hedge funds and other institutional investors.
Humana (NYSE HUM) opened at $273.11 on Wednesday. Humana has a 12 month low of $203.48 and a 12 month high of $293.35. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.85 and a current ratio of 1.85. The stock has a market capitalization of $39,020.00, a PE ratio of 15.51, a P/E/G ratio of 1.46 and a beta of 0.95.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be issued a $0.50 dividend. This is an increase from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a dividend yield of 0.73%. The ex-dividend date is Wednesday, March 28th. Humana’s payout ratio is presently 9.09%.
Humana declared that its Board of Directors has approved a stock repurchase program on Thursday, December 14th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the insurance provider to repurchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.